Welcome to our dedicated page for Jyong Biotech Ltd. SEC filings (Ticker: MENS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jyong Biotech Ltd. (Nasdaq: MENS) SEC filings page on Stock Titan is designed to help readers review the company’s U.S. regulatory disclosures in one place. As a foreign private issuer in the biotechnology sector focused on plant-derived drugs for urinary system diseases, Jyong Biotech uses SEC filings to describe its business, risk factors, pipeline, and capital-raising activities.
Key documents for MENS include the registration statement on Form F-1 related to its initial public offering and subsequent reports such as Forms 6-K, which the company references in its news releases. These filings provide detail on the company’s lead botanical drug candidates, including MCS-2 and MCS-8, its clinical trial programs in BPH, LUTS, and prostate cancer prevention, and its intended use of IPO proceeds for Phase III and earlier-stage trials, regulatory submissions, and general corporate purposes.
Through Stock Titan, users can access real-time updates from EDGAR as new MENS filings are posted, including prospectuses, current reports, and other required disclosures. AI-powered summaries help explain the structure and implications of lengthy documents, highlighting sections related to clinical development plans, intellectual property, regional licensing strategies, and financial commitments.
Investors interested in insider activity and governance can also use SEC data to review information on share offerings and other transactions as disclosed in Jyong Biotech’s filings. While specific forms such as Form 4 or proxy statements may be more limited for some foreign issuers, the available filings still provide context on ownership, potential dilution, and board-level decisions.
By using the MENS SEC filings page with AI-assisted insights, readers can more easily interpret Jyong Biotech’s regulatory disclosures, understand how its botanical drug pipeline is described to regulators, and see how capital raised on Nasdaq is allocated across its development programs.
Jyong Biotech Ltd. reported unaudited interim results for the six months ended June 30, 2025, showing a net loss of $1,252k, slightly improved from $1,326k a year earlier. Operating expenses fell to $816k from $951k, mainly due to lower research and development spending, while interest income rose to $24k and interest expenses were $417k.
Total assets increased sharply to $37,671k as of June 30, 2025 from $6,366k at December 31, 2024, driven by new short-term investments of $16,875k and a $15,000k loan receivable from a shareholder. Cash and restricted cash together remained modest. Total liabilities rose to $60,143k, including higher short-term bank loans of $22,436k and long-term loans from related parties of $7,195k.
The company continued to report a shareholders’ deficit, although it narrowed to $(22,472k) from $(36,519k), helped by higher additional paid-in capital of $28,263k. Basic and diluted net loss per share stayed at $(0.02), on a weighted average of about 71,758k shares.
FAQ
What is the current stock price of Jyong Biotech Ltd. (MENS)?
What is the market cap of Jyong Biotech Ltd. (MENS)?
